Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Vertex Pharmaceuticals has led the cystic fibrosis (CF) drug market since its first approval in 2012, with most revenue still coming from its CF franchise. In the second quarter, Vertex reported $3.33 billion in revenue, up 12% year over year, including $3.2 billion from CF-related sales. The article argues that new competition could erode Vertex’s pricing power, potentially pressuring revenue and earnings. It points to Sionna Therapeutics, a clinical-stage biotech focused exclusively on CF, valued at about $2.2 billion versus Vertex’s nearly $123 billion. The comparison centers on Sionna’s claim that its approach could restore CFTR protein function more directly than Vertex’s medicines. However, Sionna’s lead programs remain in Phase 2 studies.